The randomized clinical trial (RCT) represents the highest level of evidence for therapeutic efficacy and is the basis for registration of new products by health care agencies across the world. 1 Among its many beneficial qualities, randomization aims to produce unbiased effect estimates for the intervention of interest. 2 Randomization reduces the potential impact of both treatment selection bias and confounders. Randomized trials thus yield study groups that are said to be balanced, in that the distributions at baseline of variables (other than the intervention) can be expected to be similar. RCTs also have strict guidelines for public registration, conduct and standardized reporting of results which aim to ensure high quality in these studies. 3, 4 In multiple sclerosis (MS), RCTs have demonstrated the effect of disease-modifying agents in controlling disease activity and have changed the therapeutic landscape for physicians and patients. 5 However, there are circumstances in which RCTs are unfeasible, for ethical or practical reasons. RCTs occur in settings which can be quite different from "real-world" clinical practice. As a result, clinicians making decisions are unlikely to be able to answer all key questions with RCTs. In MS, RCTs provide little guidance for choices between disease-modifying agents and assessments of specific treatment algorithms, in comparison with the available clinical options. A clear need exists for observational studies to inform clinical decision-making for questions which are not answerable in RCTs. The methods used for these observational studies must be as rigorous in design and analysis, similar to what has been done for RCTs. Clinicians need to discern the quality, strengths, and weaknesses of observational studies, so that this data can adequately inform clinical practice.
The randomized clinical trial (RCT) represents the highest level of evidence for therapeutic efficacy and is the basis for registration of new products by health care agencies across the world. 1 Among its many beneficial qualities, randomization aims to produce unbiased effect estimates for the intervention of interest. 2 Randomization reduces the potential impact of both treatment selection bias and confounders. Randomized trials thus yield study groups that are said to be balanced, in that the distributions at baseline of variables (other than the intervention) can be expected to be similar. RCTs also have strict guidelines for public registration, conduct and standardized reporting of results which aim to ensure high quality in these studies. 3, 4 In multiple sclerosis (MS), RCTs have demonstrated the effect of disease-modifying agents in controlling disease activity and have changed the therapeutic landscape for physicians and patients. 5 However, there are circumstances in which RCTs are unfeasible, for ethical or practical reasons. RCTs occur in settings which can be quite different from "real-world" clinical practice. As a result, clinicians making decisions are unlikely to be able to answer all key questions with RCTs. In MS, RCTs provide little guidance for choices between disease-modifying agents and assessments of specific treatment algorithms, in comparison with the available clinical options. A clear need exists for observational studies to inform clinical decision-making for questions which are not answerable in RCTs. The methods used for these observational studies must be as rigorous in design and analysis, similar to what has been done for RCTs. Clinicians need to discern the quality, strengths, and weaknesses of observational studies, so that this data can adequately inform clinical practice.
Propensity score (PS) adjustment is one method for overcoming the potential bias inherent to observational studies. 6 In observational studies comparing the effectiveness of two or more exposures, exposure selection is not made by randomization, but typically, as a result of clinical judgment and/or patient preference. The design of an observational study requires a serious effort to minimize the potential bias that occurs when the study groups are not comparable at the moment of treatment selection. 7 The PS is the probability of assignment to a particular treatment, estimated on the basis of covariates which affect treatment selection. The data can then be adjusted using standard approaches, including matching, weighting, or stratification, so that the distributions of the estimated PS (and hence, the covariates used in modeling the PS) are similar across the treatment groups.
The most commonly used approach is PS matching, where subjects with similar PS are matched and then compared in standard effectiveness analyses for matched samples. 8 Although PS matching (and weighting, especially) are powerful tools for reducing the potential impact of treatment selection, it is crucial for authors to present details on how the propensity model was constructed and the impact of PS adjustment on the balance of the covariates of interest. Standardized differences of the covariates are a sensible choice for either tables or (better) figures, permitting readers to see residual bias directly across the range of covariates. 9, 10 In the case of significant results, in particular, a formal sensitivity analysis using Rosenbaum sensitivity bounds should be included to estimate the size of the impact required in a hypothetical unmeasured confounder in order to change the conclusions. 11 In this issue of Multiple Sclerosis Journal (MSJ), Baroncini and colleagues report on an observational study of 102 matched pairs treated with either fingolimod or natalizumab. 12 The authors found that subjects treated with natalizumab had a higher likelihood of remaining relapse free over the 24-month follow-up. Similar results favoring natalizumab included magnetic resonance imaging (MRI) activity and no evidence of disease activity. The study answers an important clinical question of comparative efficacy of two commonly used MS disease-modifying agents and displays several good practices regarding PS methods. The authors described the covariates used for the PS model as well as the selection criteria for matching (caliper of 0.05). Importantly, the authors used disease activity in the year prior to therapy initiation as a covariate. The authors present standardized differences for all covariates and display the improvement seen after propensity matching. The annualized relapse rate in the unmatched cohort was significantly different in the fingolimod-and natalizumab-treated patients, but this difference disappeared in the PS matched group. The two sensitivity analyses (matching by PS and adjusting for PS) add only minimal additional information and may provide a somewhat false sense of security, since neither directly addresses the potential impact of hidden bias, which is the major concern in applying PS. The sensitivity analysis should have addressed if all important covariates that relate to treatment selection are included in the PS, with the result being no hidden bias after PS matching. Rosenbaum bounds, and related approaches 8 would be helpful in this case to describe the size of hidden bias that would be required to invalidate the significant conclusions of the matched-pair analysis.
Covariate imbalance for several key measures was still large for certain variables including disease activity, disease duration, and presence of enhancing lesions. This needs to be taken into account when analyzing the outcomes. It also appears that PS matching actually increased the differences in disease duration, which could have been addressed with more advanced PS methods. MRI outcomes were relatively crude, with only a dichotomous determination of presence/absence of lesions. This was likely due to the fact that data were extracted from the medical record rather than a centralized MRI analysis. Improvement in the Expanded Disability Status Score (EDSS) may have had more to do with variable distribution of relapse recovery in the two groups rather than a clear medication effect.
The paper of Baroncini is an example of the potential use of observational studies to answer clinically meaningful questions. The study demonstrates a benefit of natalizumab over fingolimod on several key efficacy measures, although some methodological limitations are present. Although care was taken to adjust for potential confounders and partial assessment of potential confounders was made, a proper sensitivity analysis was lacking. Nonetheless, this type of study provides some useful estimates which may be helpful for clinicians and patients faced with a decision for which RCT data are unavailable and unlikely to be available in the near future.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.O. has acted as a consultant for Acorda, Alkermes, Biogen Idec, Genentech, Genzyme, Mallinckrodt, Novartis, Synthon and has received research funds from Genzyme, Novartis, National Multiple Sclerosis Society, and the National Institutes of Health. T.E.L. reports no disclosures.
